We Are Innovators
WE ARE REFLEXION
ABOUT
AN ENTIRELY NEW CLASS OF THERAPEUTICS: SYNTHETIC D-PROTEINS
Reflexion Pharmaceuticals has developed a novel platform utilizing the tools of synthetic biology to discover, develop and deliver an exciting new class of drug products: completely synthetic proteins composed entirely of D-amino acids. These synthetic D-proteins exhibit the benefits of antibodies while overcoming many of their limitations including reduced size, no immunogenicity, and improved stability. Our platform technology allows us to pursue virtually any disease target and shows enormous potential.
TECH
ENGINEERING MIRROR-IMAGE MEDICINE
We use a technique called mirror-image phage display to engineer synthetic D-protein therapies against a broad range of disease targets. After we identify our target protein in its naturally occurring L-form, we chemically synthesize its mirror-image enantiomer using D-amino acids. We then use several rounds of phage display to evolve high-affinity binding variants against this mirror-image of the disease target. Finally, we chemically synthesize these binders as D-proteins that act as highly potent antagonists to the disease targets in vivo.
ADVANTAGES
SMALL SIZE
Our synthetic D-proteins are 20X smaller than antibodies yet have equivalent potencies, allowing higher molar concentrations to be used
NON-IMMUNOGENIC
Synthetic D-proteins are resistant to degradation by proteases, extending their residence time and preventing the activation of anti-drug immune responses
THERMAL STABILITY
Our D-proteins are engineered for high thermal and chemical stability, eliminating the need for a cold chain
OUR THERAPEUTIC PIPELINE
ASSETS
ANTI-
PD-1
PD-1 inhibitors are the most exciting class of therapeutics to be discovered in the last decade. These molecules release the "brakes" on our immune systems, stimulating a full-on assault against cancerous cells
IMMUNO-ONCOLOGY
ANTI-
PD-1
ANTI-
VEGF
VEGF is a primary target for treatment of wet macular degeneration, and has recently demonstrated tremendous success in the clinic in combination with PD-1 inhibitors for treating a number of different cancers
MACULAR DEGENERATION, ONCOLOGY
ANTI-
VEGF
TEAM
WHO WE ARE
DANA AULT-RICHE, PHD
DAVID CHERNOFF, MD
GREG WENT, PHD
KYLE LANDGRAF, PHD
MARCY BETH NANUS
NATALIE MCLURE, PHD
PAUL STEPHEN MARINEC, PHD
RICHARD VAN DEN BROEK
ROWAN CHAPMAN, PHD
SACHDEV SIDHU, PHD
STEPHEN KENT, PHD
VED SRIVASTAVA, PHD
GET IN TOUCH
